{
  "patient_id": "MBC_002",
  "subtype": "TNBC",
  "biomarker_summary": {
    "ER": "negative",
    "PgR": "negative",
    "HER2": "negative",
    "PIK3CA": "wild_type",
    "BRCA1": "mutant",
    "BRCA2": "wild_type",
    "PALB2": "wild_type",
    "MSI": "stable",
    "TMB": 8.5
  },
  "treatment_history_summary": "1 prior line(s), last: carboplatin + paclitaxel",
  "recommendations": [
    {
      "treatment": "Sacituzumab Govitecan",
      "evidence_level": "I",
      "recommendation_strength": "Strong",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Breast Cancer Subtype Classification -> Triple\u00e2\u20ac\u2018Negative Breast Cancer (TNBC) -> TNBC Second\u00e2\u20ac\u2018line (requires prior progression)",
      "rationale": "Patient has TNBC metastatic breast cancer. Recommended after progression on 1 prior line(s).",
      "keywords": [
        "metastatic breast cancer",
        "sacituzumab govitecan",
        "antibody drug conjugate",
        "systemic therapy",
        "Trop-2",
        "ADC"
      ]
    },
    {
      "treatment": "Standard single\u00e2\u20ac\u2018agent chemo",
      "evidence_level": "I",
      "recommendation_strength": "Moderate",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Breast Cancer Subtype Classification -> Triple\u00e2\u20ac\u2018Negative Breast Cancer (TNBC) -> TNBC Second\u00e2\u20ac\u2018line (requires prior progression)",
      "rationale": "Patient has TNBC metastatic breast cancer. Recommended after progression on 1 prior line(s).",
      "keywords": [
        "systemic therapy",
        "metastatic breast cancer"
      ]
    }
  ],
  "total_recommendations": 2
}